

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **MicroPort CardioFlow Medtech Corporation**

**微创心通医疗科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2160)**

### **PROPOSED ADOPTION OF THE AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION**

The board (the “**Board**”) of directors (the “**Directors**”) of MicroPort CardioFlow Medtech Corporation (the “**Company**”) hereby announces that at a meeting of the Board held on the date of this announcement, the relevant resolution has been passed to propose the adoption of the fifth amended and restated memorandum and articles of association of the Company (the “**Amended and Restated M&A**”) to conform to the core standards of shareholder protection, among others, adopting a uniform set of 14 core standards for shareholder protections for issuers as provided in the amended Appendix 3 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) under the new listing regime for overseas issuers which took effect on January 1, 2022 (the “**New Listing Regime**”) and to incorporate certain housekeeping amendments. The proposed adoption of the Amended and Restated M&A is subject to the approval of the shareholders of the Company (the “**Shareholders**”) by way of a special resolution at the forthcoming annual general meeting of the Company (the “**AGM**”).

This announcement is made by the Company pursuant to Rule 13.51(1) of the Listing Rules.

### **PROPOSED ADOPTION OF THE AMENDED AND RESTATED M&A**

The Board has resolved at the board meeting held on the date of this announcement to propose the adoption of the Amended and Restated M&A to conform to the amended Appendix 3 to the Listing Rules under the New Listing Regime, which streamlines and standardizes a uniform set of 14 core standards for shareholder protections for all issuers regardless of their place of incorporation.

The major proposed amendments to be made in the Amended and Restated M&A include:

- (i) provisions as to notice, convening and conduct of general meetings;

- (ii). provisions as to members' right to vote and speak at general meetings;
- (iii). provisions as to the use of communication facilities for the purposes of general meetings, including provisions which allow the Company to hold entirely virtual general meetings which may be attended solely by means of such communications facilities, and without a physical location;
- (iv). provisions as to the term of a director appointed by the Board either to fill a casual vacancy or as an addition to the Board;
- (v). provisions as to reserving (a) approval of appointment, removal and remuneration of auditors to the shareholders by way of ordinary resolutions; and (b) approval of winding up the Company to the shareholders by way of special resolution;
- (vi). other amendments for house-keeping purposes in line with the proposed amendments in (i) to (v) above pursuant to the Listing Rules and the applicable laws of the Cayman Islands; and
- (vii). other miscellaneous amendments to update or clarify provisions where it is considered desirable.

## **EFFECTIVE DATE OF THE AMENDED AND RESTATED M&A**

The proposed adoption of the Amended and Restated M&A is subject to the approval by the Shareholders by way of a special resolution to be considered and, if thought fit, passed at the forthcoming AGM. The Amended and Restated M&A shall take immediate effect upon the close of the AGM at which the relevant special resolution has been passed.

## **CIRCULAR**

A circular containing, among other things, details of the proposed adoption of the Amended and Restated M&A, together with a notice convening the AGM, will be despatched to the Shareholders in due course.

By order of the Board  
**MicroPort CardioFlow Medtech Corporation**  
**Luo Qiyi**  
*Chairman*

Shanghai, PRC, March 29, 2023

*As at the date of this announcement, the executive Directors are Mr. Chen Guoming, Mr. Zhao Liang and Ms. Yan Luying, the non-executive Directors are Dr. Luo Qiyi, Mr. Zhang Junjie and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Ding Jiandong and Ms. Sun Zhixiang.*